Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “

Other analysts also recently issued reports about the company. HC Wainwright set a $7.00 price target on Trillium Therapeutics and gave the stock a “buy” rating in a report on Monday, August 14th. Cowen and Company reaffirmed a “buy” rating on shares of Trillium Therapeutics in a report on Wednesday, July 5th. Finally, Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $18.00 price target on shares of Trillium Therapeutics in a report on Friday, June 9th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $14.95.

Shares of Trillium Therapeutics (TRIL) opened at 5.051 on Tuesday. The stock’s market capitalization is $54.52 million. Trillium Therapeutics has a 52 week low of $4.15 and a 52 week high of $17.70. The company’s 50 day moving average price is $4.63 and its 200-day moving average price is $5.28.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/19/trillium-therapeutics-inc-tril-rating-increased-to-hold-at-zacks-investment-research.html.

Several institutional investors have recently bought and sold shares of TRIL. NEA Management Company LLC purchased a new stake in shares of Trillium Therapeutics in the 2nd quarter valued at about $4,619,000. AWM Investment Company Inc. purchased a new stake in shares of Trillium Therapeutics in the 2nd quarter valued at about $4,415,000. Janus Henderson Group PLC purchased a new stake in shares of Trillium Therapeutics in the 2nd quarter valued at about $2,395,000. Tekla Capital Management LLC purchased a new stake in shares of Trillium Therapeutics in the 2nd quarter valued at about $1,980,000. Finally, Victory Capital Management Inc. lifted its holdings in shares of Trillium Therapeutics by 88.9% in the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 68,970 shares during the last quarter. 47.97% of the stock is owned by institutional investors and hedge funds.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Analyst Recommendations for Trillium Therapeutics (NASDAQ:TRIL)

Receive News & Stock Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related stocks with our FREE daily email newsletter.